COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-mutated NSCLC
Sorry, I don’ t understand. Please try again The first interim analysis of the Phase 2 COCOON study met its primary endpoint, demonstrating that an easy-to-use and readily available regimen significantly reduced the frequency of moderate-to-severe skin and nail side effects (Grade 2 or higher) and severity of skin-related side effects compared to standard dermatological management in patients receiving first-line treatment with RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib). The study enrolled
